Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05557370 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immunogenicity of HPV Vaccine in Transplant Recipients.

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 31, 2025 to Dec 31, 2028v7
  2. Trial status: Recruiting to Active, Not Recruiting Site details revisedv6 Show 1 more changeShow less
    • Site details revised
  3. Enrollment target: 100 to 30 Eligibility criteria shortened, about 49 words · Study description shortened, about 72 words · Study arms: 2 to 1v5 Show 3 more changesShow less
    • Eligibility criteria shortened, about 49 words
    • Study description shortened, about 72 words
    • Study arms: 2 to 1

    See this version in full on ClinicalTrials.gov ↗

  4. Phase: Not specified to Phase 4v4
  5. Re-verified, no change to tracked fieldsv3
  6. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 2022 to Jun 1, 2023 · Secondary endpoints: details revised at 1 of 1 entry · Site details revised · 1 morev2 Show 4 more changesShow less
    • Start date changed from estimate of Oct 2022 to Jun 1, 2023
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised
    • Study description shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To measure levels of HPV antibodies in post-solid-organ transplant recipients who have gotten the HPV9 vaccine.
Trial Details
NCT Number NCT05557370
Lead Sponsor Medical College of Wisconsin
Collaborators: Merck Sharp & Dohme LLC
Conditions Chronic Kidney Diseases, Kidney Transplant
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov